Sports & regenerative medicine division of Vector Science & Therapeutics · TSXV: PAIN
Exclusive investor updates on company milestones, patent developments, athlete partnerships and regulatory progress — sent directly, before the noise.
Capacity and patent figures as disclosed by Vector Science & Therapeutics.
Receive updates on company milestones, scientific advancements, patents, partnerships, and investor news.
Watch your inbox — you'll receive Valor and Vector announcements as they're released.
Live market data
—
Quotes may be delayed by up to 15 minutes and are provided for information only. Nothing on this page is investment advice or an offer to sell securities.
What is Valor?
Valor is the sports and regenerative medicine division of Vector Science & Therapeutics (TSXV: PAIN) — built to develop relationships across professional and elite athletics and to advance recovery, soft tissue repair and non-opioid pain management around Vector's localized delivery technology.
Division scope per the Vector Science newsroom and the June 2026 Valor announcement.
About Vector Science
Vector Science & Therapeutics develops localized therapeutic delivery technologies designed to deliver treatment directly to the site of disease or injury. Our platform focuses on precision delivery that supports clinicians when targeted intervention is more appropriate than systemic therapy.
See the TSXV listing release and the Q1 public-company results.
Team Valor
Valor pairs Vector’s medical technology and clinical leadership with athletes who have competed at the highest level and understand what recovery actually costs.
Chief Executive Officer · Vector Science & Therapeutics
25+ years in medical technology, including co-founding Attwill Medical Solutions. Bill’s track record of scaling MedTech companies from concept to clinical adoption positions Vector Science for aggressive, disciplined growth in the precision therapeutics market.
Chief Medical Officer · Vector Science & Therapeutics
Board-certified anesthesiologist with deep clinical expertise in perioperative care and localized intervention. Dr. Worthington provides critical clinical perspective to product development, ensuring Vector’s platforms meet the practical demands of real-world patient care and regulatory standards.
President of Valor · Chairman, Athletic Board
Leads Valor's commercial strategy, athlete partnership development and market expansion, bringing more than a decade of building high-performance commercial teams internationally.
Announcement →
Chief Athletic Ambassador
2022 NBA Champion and Golden State Warriors guard. Serves as the face of Valor inside the NBA and across professional sports, and is the founder of the GPII Foundation.
Announcement →
Chief Athletic Officer
2016 World Series Champion and Olympic bronze medalist. Leads athlete engagement and onboarding across professional sports for the Valor platform.
Announcement →
Athlete Advisor
NBA guard. Advises Valor on the realities of in-season recovery, soft tissue durability and the day-to-day demands placed on professional athletes.
Investor community
Everything Vector and Valor announces — as it happens.
Operational and commercial progress, reported first-hand.
New filings and movement across the delivery IP portfolio.
Appointments to the board, the executive team and the Athletic Board.
New ambassadors, advisors and professional sports relationships.
Quarterly filings, financings and capital markets activity.
Manufacturing, licensing and distribution agreements.
Context on peptides, pain management and sports medicine markets.
Interviews, features and broadcast segments.
Investor Q&A sessions, conferences and webcasts.
Submission and clearance progress, including VectorMist™ 510(k).
Credibility
Real-world evidence
A multi-phase real-world evidence program, culminating in a prospective comparative registry across partner surgical facilities, comparing postoperative outcomes for VectorMist™ and The LASSO Protocol™.
July 17, 2026 →Manufacturing
An exclusive licensing and long-term cGMP manufacturing relationship covering Vector's proprietary peptide portfolio, based in Mequon, Wisconsin.
July 7, 2026 →Development
A three-year development and manufacturing agreement providing access to an FDA-registered cGMP facility and supporting development of novel shelf-stable peptide formulations.
May 11, 2026 →Milestones
Only publicly announced developments appear below.
Definitive agreement announced with OpenSesame Acquisition Corp., the step toward a public listing.
Qualifying transaction completed; shares begin trading under the symbol PAIN.
Release →A microneedle catheter platform for intratumoral drug delivery research, with an initial focus on pancreatic cancer.
Release →Three-year development and manufacturing agreement providing access to an FDA-registered cGMP facility.
World Series champion and Olympic medalist takes on athlete engagement and onboarding across professional sports.
NBA champion joins Valor to help bring non-addictive recovery and pain management approaches to professional athletes.
Release →Licensing and long-term manufacturing relationship established with LyoGenesis Plus for the proprietary peptide portfolio.
Drake takes on the presidency of Valor and the chair of the Athletic Board as Vector targets the performance medicine market.
Release →Patent estate spans peptide and biologic delivery, opioid-sparing pain management, regenerative medicine and smart wound care.
Real-world evidence infrastructure established for VectorMist™ and The LASSO Protocol™.
Dedicated distributor network announced for the peptide portfolio across orthopedic, sports and regenerative medicine channels.
Release →Peptide manufacturing revenue expected in August 2026; VectorMist™ 510(k) submission advancing toward FDA filing.
Release →LyoGenesis Plus and Wynn Pharmaceuticals sign an MOU to develop IV bag and vial adaptor products.
Amended and restated exclusive licence and manufacturing agreement with LyoGenesis Holdings, effective August 13 and announced August 17. Initial ten-year term, renewing annually.
Release →MPP Group LLC relaunches as Verlytix, the quality and analytical testing affiliate of LyoGenesis Manufacturing, testing Vector’s peptides for sterility, purity, potency, endotoxin and water content.
Release →USPTO filing covering tissue-repair peptides paired with a patient’s own platelet-rich plasma or fibrin, including sequencing designed to avoid conflicts with agents used routinely in orthopedic surgery. Pre-clinical; no clinical studies conducted.
Release →The first of four suites at LyoGenesis Manufacturing comes online at roughly 55,000 vials per month — production already presold. The remaining three suites are expected in the second half of September.
Release →Twelve-month investor relations agreement with RedChip Companies, with 150,000 options granted at C$1.80, subject to TSX Venture Exchange approval.
Release →Three further manufacturing suites in the second half of September, regulatory progress and further athlete partnerships. Announced to the investor list first.
Join Investor UpdatesInvestor news
August 25, 2026 · Investor relations
August 24, 2026 · Manufacturing
August 20, 2026 · Intellectual property
August 18, 2026 · Partner
August 17, 2026 · Agreement
July 28, 2026 · Press release
July 24, 2026 · Financial results
July 21, 2026 · Commercial
Contact
Parent company
Valor is the sports & regenerative medicine division of Vector Science & Therapeutics.
For corporate, regulatory or supplier enquiries that sit outside Valor, contact Vector directly.
Contact Vector Science & Therapeutics
info@vectorscience.co (833) 832-8724
12250 Corporate Parkway
Mequon, WI 53092
FAQ
Valor is the sports and regenerative medicine division of Vector Science & Therapeutics Corp. It develops relationships across professional and elite athletics and builds the commercial framework supporting Vector's transdermal peptide delivery technology for recovery, soft tissue repair and non-opioid pain management.
Valor is a division within Vector, not a separate public company. Vector Science & Therapeutics Corp. trades on the TSX Venture Exchange under the symbol PAIN.
Company milestones, patent developments, leadership appointments, athlete partnerships, business and manufacturing developments, regulatory progress, financial filings, media appearances and event invitations.
The list is announcement-driven rather than on a fixed schedule. You'll hear from us when there is something material to share — not to fill a calendar slot.
Yes. Every email includes a one-click unsubscribe link, and you can opt out at any time without affecting anything else.
No. This page and the investor list are informational only. Nothing here is investment advice, a recommendation, or an offer to sell or a solicitation to buy securities. Consult your own advisors and review Vector's filings on SEDAR+.
Still deciding? The list is the easiest way to follow the story.
Join Investor UpdatesReceive every major company announcement directly in your inbox.
Announcements will arrive as they're released.
Never miss an update.Milestones, patents, athlete news.
Join Investor Updates